

IMPORTANT SAFETY INFORMATION AND USE

WHAT IS ABRYSVO?

ABRYSVO is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

IMPORTANT SAFETY INFORMATION

- ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
- An increased risk of Guillain-Barré syndrome (severe muscle weakness) was observed after vaccination with ABRYSVO

Please see additional Important Safety Information on pages 2-6. Please see full Prescribing Information for ABRYSVO.



IMPORTANT SAFETY INFORMATION (cont'd)

- To avoid the potential risk of preterm birth, ABRYSVO should be given during 32 through 36 weeks gestational age
- Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
- Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO



Here's how ABRYSVO works



During pregnancy, your body naturally passes on antibodies that help protect your baby against bacteria and viruses, like RSV.




Getting ABRYSVO while pregnant **helps your body create RSV antibodies that are passed to your baby**, allowing for the earliest protection for your baby from the moment they are born through 6 months.

You may be eligible to get ABRYSVO at no cost through insurance. Check coverage options and savings support at <u>ABRYSVO.com</u>

IMPORTANT SAFETY INFORMATION (cont'd)

- Vaccination with ABRYSVO may not protect all people
- In pregnant individuals, the most common side effects (≥10%) were pain at the injection site, headache, muscle pain, and nausea
- In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals
 experienced low birth weight (5.1% ABRYSVO versus 4.3% placebo) and jaundice (7.3% ABRYSVO
 versus 6.9% placebo)



How was Pfizer's ABRYSVO® studied in pregnant women?

ABRYSVO was studied in clinical trials including over 7,000 pregnant women and their babies, where 3,698 pregnant women received ABRYSVO and 3,687 received a placebo.

What were the most common side effects of Pfizer's ABRYSVO in its clinical trial?

- Pregnant women who received ABRYSVO most commonly reported pain at the injection site, headache, muscle pain, and nausea
- Jaundice, also known as temporary yellowing of the eyes and skin, was seen in
 7.3% of infants in the ABRYSVO group and 6.9% in the placebo group
- Low birth weight was observed in 5.1% of infants in the ABRYSVO group versus 4.3% in the placebo group

The CDC recommends ABRYSVO if you are **32 through 36 weeks pregnant during RSV season—from September through January** in most of the U.S. There are areas in the U.S., including southern FL, AK, HI, and the U.S. territories, where RSV does not follow typical seasonal patterns and the recommended months for maternal vaccination may differ. **Vaccination with ABRYSVO may not protect everyone.**

Talk to your OB-GYN about protecting your baby against RSV from birth with ABRYSVO

Using your due date and location, you can check your eligibility for ABRYSVO. Visit <u>abrysvo.com/maternal-rsv-vaccine-planner</u>

RSV=respiratory syncytial virus.

IMPORTANT SAFETY INFORMATION (cont'd)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

Please see additional Important Safety Information on pages 1-6. Please see full Prescribing Information for ABRYSVO.



- For over 20 years, pregnant women have been receiving the
 Tdap vaccine to help protect their babies from whooping cough
- ABRYSVO® works similarly to the Tdap vaccine, helping your body create antibodies that are passed to your unborn baby

IMPORTANT SAFETY INFORMATION (cont'd)

You are encouraged to report side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Individuals who received ABRYSVO during pregnancy are encouraged to enroll in a pregnancy exposure registry at 1-800-616-3791. The registry will monitor pregnancy outcomes.



Talk to your OB-GYN about getting vaccinated during pregnancy with ABRYSVO

SELECT IMPORTANT SAFETY INFORMATION (cont'd)

ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components

Please see additional Important Safety Information on pages 1-6. Please see full Prescribing Information for ABRYSVO.

